Literature DB >> 24604209

A high-affinity near-infrared fluorescent probe to target bombesin receptors.

Ajay Shrivastava1, Haiming Ding, Shankaran Kothandaraman, Shu-Huei Wang, Li Gong, Michelle Williams, Keisha Milum, Song Zhang, Michael F Tweedle.   

Abstract

PURPOSE: This study aimed to create new optical surgical navigation NIRF probes for prostate and breast cancers. PROCEDURES: IR800-linker-QWAVGHLM-NH2 with linker = GSG, GGG, and G-Abz4 were synthesized and characterized. IC50 for bombesin receptors (BBN-R) in PC-3 prostate and T47D breast cancer cells, fluorescence microscopy in PC-3 cells, and NIRF imaging in mice PC-3 tumor xenografts were studied.
RESULTS: GGG, GSG, and G-Abz4 derivatives had IC50 (nM) for BBN-R+ PC-3 cells = 187 ± 31, 56 ± 5, and 2.6 ± 0.2 and T47D cells = 383 ± 1, 57.4 ± 1.2, and 3.1 ± 1.1, respectively. By microscopy the Abz4 derivative showed the highest uptake, was competed with by BBN, and had little to no binding to BBN-R- cells. In NIRF imaging the G-Abz4 probe was brighter than GGG probe in BBN-R+ tissues in vivo and tissues, tumors, and tumor slices ex vivo. Uptake could be partially blocked in BBN-R+ pancreas but not visibly in tumor.
CONCLUSIONS: Linker choice can dominate peptidic BBN-R binding. The G-Abz4 linker yields a higher affinity and specific BBN-R binder in this series of molecules.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24604209      PMCID: PMC5885141          DOI: 10.1007/s11307-014-0727-2

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  43 in total

Review 1.  Image-guided surgery in head and neck cancer: current practice and future directions of optical imaging.

Authors:  S Keereweer; H J C M Sterenborg; J D F Kerrebijn; P B A A Van Driel; R J Baatenburg de Jong; C W G M Löwik
Journal:  Head Neck       Date:  2011-01-31       Impact factor: 3.147

2.  Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigen.

Authors:  Tiancheng Liu; Jessie R Nedrow-Byers; Mark R Hopkins; Clifford E Berkman
Journal:  Bioorg Med Chem Lett       Date:  2011-10-04       Impact factor: 2.823

Review 3.  Peptides and peptide hormones for molecular imaging and disease diagnosis.

Authors:  Seulki Lee; Jin Xie; Xiaoyuan Chen
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

4.  Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck.

Authors:  Miriam N Lango; Kevin F Dyer; Vivian Wai Yan Lui; William E Gooding; Christopher Gubish; Jill M Siegfried; Jennifer Rubin Grandis
Journal:  J Natl Cancer Inst       Date:  2002-03-06       Impact factor: 13.506

Review 5.  Candidates for peptide receptor radiotherapy today and in the future.

Authors:  Jean Claude Reubi; Helmut R Mäcke; Eric P Krenning
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

6.  Pharmacokinetics, lymph node uptake, and mechanistic PK model of near-infrared dye-labeled bevacizumab after IV and SC administration in mice.

Authors:  Fang Wu; Mitalee Tamhane; Marilyn E Morris
Journal:  AAPS J       Date:  2012-03-06       Impact factor: 4.009

Review 7.  Peptide-based probes for cancer imaging.

Authors:  Jean Claude Reubi; Helmut R Maecke
Journal:  J Nucl Med       Date:  2008-10-16       Impact factor: 10.057

8.  Fluorescent fructose derivatives for imaging breast cancer cells.

Authors:  Jelena Levi; Zhen Cheng; Olivier Gheysens; Manish Patel; Carmel T Chan; Yingbing Wang; Mohammad Namavari; Sanjiv Sam Gambhir
Journal:  Bioconjug Chem       Date:  2007-04-20       Impact factor: 4.774

9.  Evaluation of the pharmacokinetic effects of various linking group using the 111In-DOTA-X-BBN(7-14)NH2 structural paradigm in a prostate cancer model.

Authors:  Jered C Garrison; Tammy L Rold; Gary L Sieckman; Farah Naz; Samantha V Sublett; Said Daibes Figueroa; Wynn A Volkert; Timothy J Hoffman
Journal:  Bioconjug Chem       Date:  2008-08-20       Impact factor: 4.774

10.  Radiolabeled peptides: valuable tools for the detection and treatment of cancer.

Authors:  M Fani; H R Maecke; S M Okarvi
Journal:  Theranostics       Date:  2012-05-16       Impact factor: 11.556

View more
  11 in total

1.  Novel Gastrin-Releasing Peptide Receptor Targeted Near-Infrared Fluorescence Dye for Image-Guided Surgery of Prostate Cancer.

Authors:  Amerigo Pagoto; Francesca Garello; Giada Maria Marini; Martina Tripepi; Francesca Arena; Paola Bardini; Rachele Stefania; Stefania Lanzardo; Giovanni Valbusa; Francesco Porpiglia; Matteo Manfredi; Silvio Aime; Enzo Terreno
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

2.  A 3E8.scFv.Cys-IR800 Conjugate Targeting TAG-72 in an Orthotopic Colorectal Cancer Model.

Authors:  Li Gong; Haiming Ding; Nicholas E Long; Brandon J Sullivan; Edward W Martin; Thomas J Magliery; Michael F Tweedle
Journal:  Mol Imaging Biol       Date:  2018-02       Impact factor: 3.488

Review 3.  Nano-Theranostics for the Sensing, Imaging and Therapy of Prostate Cancers.

Authors:  David G Calatayud; Sotia Neophytou; Eleni Nicodemou; S Giuseppe Giuffrida; Haobo Ge; Sofia I Pascu
Journal:  Front Chem       Date:  2022-04-12       Impact factor: 5.545

4.  A human GRPr-transfected Ace-1 canine prostate cancer model in mice.

Authors:  Haiming Ding; Shankaran Kothandaraman; Li Gong; Michelle M Williams; Wessel P Dirksen; Thomas J Rosol; Michael F Tweedle
Journal:  Prostate       Date:  2016-03-04       Impact factor: 4.104

5.  Multimodal molecular 3D imaging for the tumoral volumetric distribution assessment of folate-based biosensors.

Authors:  Gerardo J Ramírez-Nava; Clara L Santos-Cuevas; Isaac Chairez; Liliana Aranda-Lara
Journal:  Med Biol Eng Comput       Date:  2017-12-01       Impact factor: 2.602

6.  Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.

Authors:  Hanwen Zhang; Pooja Desai; Yusuke Koike; Jacob Houghton; Sean Carlin; Nidhi Tandon; Karim Touijer; Wolfgang A Weber
Journal:  J Nucl Med       Date:  2016-08-11       Impact factor: 10.057

7.  Development of an orthotopic canine prostate cancer model expressing human GRPr.

Authors:  Michael F Tweedle; Haiming Ding; William T Drost; Joshua Dowell; James Spain; Mathew Joseph; Said M Elshafae; Maria-Isabela Menendez; Li Gong; Shankaran Kothandaraman; Wessel P Dirksen; Chadwick L Wright; Robert Bahnson; Michael V Knopp; Thomas J Rosol
Journal:  Prostate       Date:  2018-07-11       Impact factor: 4.104

8.  68Ga-radiolabeled bombesin-conjugated to trimethyl chitosan-coated superparamagnetic nanoparticles for molecular imaging: preparation, characterization and biological evaluation.

Authors:  Maliheh Hajiramezanali; Fatemeh Atyabi; Mona Mosayebnia; Mehdi Akhlaghi; Parham Geramifar; Amir Reza Jalilian; Seyed Mohammad Mazidi; Hassan Yousefnia; Soraya Shahhosseini; Davood Beiki
Journal:  Int J Nanomedicine       Date:  2019-04-10

9.  GRPR-targeted Protein Contrast Agents for Molecular Imaging of Receptor Expression in Cancers by MRI.

Authors:  Fan Pu; Jingjuan Qiao; Shenghui Xue; Hua Yang; Anvi Patel; Lixia Wei; Khan Hekmatyar; Mani Salarian; Hans E Grossniklaus; Zhi-Ren Liu; Jenny J Yang
Journal:  Sci Rep       Date:  2015-11-18       Impact factor: 4.379

10.  How gastrin-releasing peptide receptor (GRPR) and αvβ3 integrin expression reflect reorganization features of tumors after hyperthermia treatments.

Authors:  Sandra Hallasch; Sindy Frick; Maximilian Jung; Ingrid Hilger
Journal:  Sci Rep       Date:  2017-07-31       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.